Mark Donnison

Medical Australia Pty Ltd. engages in the development, manufacture, and distribution of medical devices and consumables used in the human and animal healthcare markets. It offers medication delivery, reuse prevention, and surgical devices. It operates through the following geographical segments: Australia, Asia, New Zealand, and United Kingdom. The company was founded on February 28, 2001 and is headquartered in Lidcombe, Australia.

Alphapharm has been developing and making generic medicines in Australia for more than 25 years. Millions of Australians take an Alphapharm generic medicine every day. In fact, It has become the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme and Australia's leader in generic medicines. Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US. Globally, Alphapharm is part of Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third-largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.